Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
← catalyst calendarNCT07160179 · readout ≤ 1,169 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
66estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-13 | actual | When the study began enrolling |
| Primary completion | Oct 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Geographic Atrophy
- Age-Related Macular Degeneration
Interventions
- Drug: ABBV-6628
- Drug: SYFOVRE
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to approximately 25 months
Number of Participants with Abnormal Change in Physical Examinations
measured Up to approximately 25 months
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
measured Up to approximately 25 months
Change From Baseline in Electrocardiograms (ECGs)
measured Up to approximately 25 months
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
measured Up to approximately 25 months
Change from baseline in Best Corrected Visual Acuity (BCVA)
measured Up to approximately 25 months
Change in Slit lamp biomicroscopy assessment
measured Up to approximately 25 months
Change in Intraocular pressure (IOP)
measured Up to approximately 25 months
Change in Lens examination assessment
measured Up to approximately 25 months
Change in Ophthalmoscopy assessment
measured Up to approximately 25 months
Change in fundus autofluorescence (FAF) imaging assessed by Investigator
measured Up to approximately 25 months
Change in Retinal evaluation
measured Up to approximately 25 months
Change in spectral domain optical coherence tomography (SD-OCT)
measured Up to approximately 25 months
Change in Fluorescein angiography (FA) assessed by Investigator.
measured Up to approximately 25 months
Change in choroidal neovascularization (CNV) assessed by Investigator.
measured Up to approximately 25 months
Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the Investigator
measured Up to approximately 25 months
Maximum Serum Concentration (Cmax) of ABBV-6628
measured Up to approximately 25 months
Time to Cmax (Tmax) of ABBV-6628
measured Up to approximately 25 months
Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628
measured Up to approximately 25 months
Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628
measured Up to approximately 12 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed